Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Meningioma 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Hemangiopericytoma, Malignant 1Central Nervous System Neoplasms 1Brain Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Hydroxyurea 3Bevacizumab 3pembrolizumab 2Imatinib Mesylate 2Everolimus 2vistusertib 1vatalanib 1pasireotide 1fludarabine phosphate 1fludarabine 1arginyllysine 1antineoplaston AS 2-1 1antineoplaston A10 1aldesleukin 1Whole Body Imaging 1Verapamil 1Sunitinib 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Radiotherapy, Conformal 1Radiotherapy 1Radiosurgery 1Proton Therapy 1Nivolumab 1Modafinil 1Magnetic Resonance Spectroscopy 1Ipilimumab 1HDAC-42 1Fentanyl 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Meningioma × vatalanib × Clear all
NCT00348790 2018-10-26

Vatalanib in Treating Patients With Recurrent or Progressive Meningioma

Northwestern University

Phase 2 Completed
25 enrolled 10 charts
CNSSarcoma

Hemangiopericytoma, Malignant, Brain Neoplasms, Meningioma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡